Product Features Compound: Retatrutide + Cagrilintide Concentration: 12.5mg / 2.5mg Form: Freeze-dried (lyophilized) powder Packaging: Single vial Purity: 99% Intended Use This product is for research and development purposes only
Combined administration is used anecdotally in the nootropic community but is not backed by published human data, and researchers designing combination studies should treat the interaction space as unmapped
Studies are examining how Cag influences glucagon suppression, glucose absorption, and overall glycaemic control in metabolic research models
Improved sleep quality reported as a positive effect due to melatonin-stimulating properties, but may cause drowsiness if injected in the morning
Store in cool, dry place away from light at 1-30C temperature range
Interleukin-1beta Induces ICAM-1 Expression Enhancing Leukocyte Adhesion in Human Rheumatoid Arthritis Synovial Fibroblasts: Involvement of ERK, JNK, AP-1, and NF-kappaB